Antimicrotubule Agents — oncology-focused definition
Antimicrotubule agents are a class of chemotherapy drugs that disrupt microtubule dynamics, which are essential for cell division (mitosis). They primarily arrest cells in the M phase of the cell cycle, preventing proper formation or function of the mitotic spindle.
Mechanism of Action:
- Microtubules are polymers of tubulin; they are critical for:
- Spindle formation during mitosis
- Chromosome segregation
- Intracellular transport
- Antimicrotubule agents either:
- Stabilize microtubules → prevent depolymerization (cells cannot complete mitosis)
- Destabilize microtubules → prevent polymerization (spindle cannot form)
Main Classes and Examples
| Class | Mechanism | Examples | Phase Specificity |
|---|---|---|---|
| Vinca alkaloids | Inhibit microtubule polymerization (destabilize microtubules) | Vincristine, Vinblastine, Vinorelbine | M-phase |
| Taxanes | Stabilize microtubules → prevent depolymerization | Paclitaxel, Docetaxel | M-phase |
| Epothilones | Stabilize microtubules (similar to taxanes) | Ixabepilone | M-phase |
Clinical relevance (for oncology pharmacists):
- Used in: Breast cancer, lung cancer, ovarian cancer, lymphoma, leukemia (vincristine).
- Toxicities:
- Neurotoxicity (peripheral neuropathy, especially vinca alkaloids and taxanes)
- Myelosuppression (more common with taxanes)
- Constipation (vincristine)
- Often part of combination chemotherapy regimens, e.g., CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) for lymphoma.
Key takeaway:
Antimicrotubule agents disrupt mitosis by interfering with microtubule dynamics, arresting cells in M phase, making them cell-cycle specific chemotherapeutics with unique toxicity profiles.
Links